Literature DB >> 22978488

Review of spinal neuroectodermal tumor.

Ashis Patnaik1, Sudhansu S Mishra, Sanjib Mishra, Rama C Deo.   

Abstract

Primary spinal primitive neuroectodermal tumors (PNETs) are rare tumors. Most of these tumors occur in children and young adults. To date, 47 cases of primary spinal PNET have been reported in the literature. These tumors are highly aggressive with rapid growth. Review of the literature shows that the overall prognosis of PNETs of spinal cord is very poor even with adequate surgery, radiotherapy and chemotherapy. All the cases reported to date are reviewed in terms of surgical treatment, adjuvant therapy and outcome and the experience with two of these cases are described. Both cases were thoracic extradural ones with intrathoracic extension through intervertebral foramina resembling neurofibroma. Both cases underwent gross total removal of intraspinal and thoracic component. Post-operatively both underwent cranio-spinal radiotherapy. One patient died after a post-operative period of 4 months and the other one is still alive 8 months after surgery, radiotherapy and chemotherapy.

Entities:  

Mesh:

Year:  2012        PMID: 22978488     DOI: 10.3109/02688697.2012.724120

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  3 in total

1.  Primitive neuroectodermal tumor in the spinal canal: A case report.

Authors:  Xiao-Tong Meng; Shi-Sheng He
Journal:  Oncol Lett       Date:  2015-01-27       Impact factor: 2.967

2.  Disseminated Cerebrospinal Embryonal Tumor in the Adult.

Authors:  Alessandro Caporlingua; Daniele Armocida; Federico Caporlingua; Gennaro Lapadula; Grazia Maria Elefante; Manila Antonelli; Maurizio Salvati
Journal:  Case Rep Pathol       Date:  2016-10-13

3.  Value of micro-CT for monitoring spinal microvascular changes after chronic spinal cord compression.

Authors:  Hou-Qing Long; Wen-Han Xie; Wen-Li Chen; Wen-Lin Xie; Jing-Hui Xu; Yong Hu
Journal:  Int J Mol Sci       Date:  2014-07-07       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.